BIOMAT Database Logo BIOMAT Database Logo

Neuraminidase-augmented anticarcinoembryonic antigen (CEA)-complement lysis of human colon tumor cells: lack of correlation with anti-CEA-mediated K-cell lysis and iodine-125 binding. 1979

W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic

Related Publications

W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis.
August 1975, Journal of immunology (Baltimore, Md. : 1950),
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Lysis of tumor cells by antibody and complement. 1. Lack of correlation between antigen content and lytic susceptibility.
May 1973, Journal of the National Cancer Institute,
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
K cell mediated lysis of cultured colon carcinoma and urinary bladder carcinoma cells induced by monospecific antisera against carcinoembryonic antigen (CEA) and two CEA-related normal glycoproteins.
June 1977, International journal of cancer,
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Specific lysis of human colon tumor cells by antibodies to CEA and isoantigen A: dependence on rabbit serum or neuraminidase.
November 1976, Journal of immunology (Baltimore, Md. : 1950),
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Variation in susceptibility of a human lymphoid cell line to immune lysis during the cell cycle. Lack of correlation with antigen density and complement binding.
August 1974, The Journal of experimental medicine,
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Lysis of tumor cells by antibody and complement. II. Lack of correlation between amount of C4 and C3 fixed and cell lysis.
April 1975, Journal of immunology (Baltimore, Md. : 1950),
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Quantitation of antibody-complement mediated lysis of tumor cells.
January 1977, Journal of immunological methods,
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Cell mediated cytotoxicity of human colon carcinoma cells by a monoclonal antibody (R4) recognizing the carcinoembryonic antigen (CEA) and CEA-related molecules.
June 1996, International journal of oncology,
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
131I-anticarcinoembryonic antigen therapy of LS174T human colon adenocarcinoma spheroids.
June 1989, Cancer research,
W A Tompkins, and J D Schmale, and R Mock, and N T Tick, and T Lock, and N Sidell, and J L Palmer
Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes.
May 1989, The Journal of clinical investigation,
Copied contents to your clipboard!